Sacituzumab Tirumotecan for Pancreatic Cancer
A Phase II Trial of Sacituzumab Tirumotecan for Previously Treated Locally Advanced or Metastatic Pancreatic Cancer
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: LIN YANG Doctor
- Telefonnummer: 010-13681015148
- E-Mail: linyangcicams@126.com
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Voluntary participation with written informed consent provided
- Age ≥18 years at the time of signing the informed consent form
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (including adenosquamous carcinoma)
- Failure of or disease progression after at least one prior line of systemic therapy for locally advanced or metastatic pancreatic cancer
- At least one measurable target lesion at baseline per RECIST 1.1 criteria (a single measurable lesion must not have received prior radiotherapy, or must have demonstrated clear progression after radiotherapy)
- ECOG performance status score of 0-2
- Adequate organ and bone marrow function (including hematologic, hepatic, renal, and coagulation parameters meeting specified criteria)
- Subjects of childbearing potential must use highly effective contraception, and female subjects must have a negative pregnancy test
- Ability and willingness to comply with study-related procedures.
Exclusion Criteria:
- History of or current presence of central nervous system metastases
- Presence of untreated or unstable spinal cord compression
- High risk of gastrointestinal or intra-abdominal bleeding
- Prior treatment with TROP2-targeted agents or antibody-drug conjugates (ADCs)
- Requirement for strong CYP3A4 inhibitors or inducers within 2 weeks prior to the first dose, or inability to avoid their use during the study
- History of severe dry eye syndrome, meibomian gland disease, or other corneal disorders that may impair corneal healing
- Major surgery within 28 days prior to the first dose (excluding palliative procedures), or receipt of curative radiotherapy within 3 months
- Presence of other malignancies within 3 years prior to the first treatment (except for certain definitively treated cancers)
- Uncontrolled severe systemic diseases such as cardiovascular or cerebrovascular disease, diabetes mellitus, or hypertension
- History of interstitial lung disease or non-infectious pneumonitis, or current related lesions
- Presence of severe underlying pulmonary disease, autoimmune disease, or prior total pneumonectomy
- Active chronic inflammatory bowel disease, gastrointestinal obstruction, or other severe gastrointestinal disorders
- Tumor invasion of critical organs or vessels with associated symptoms, or risk of fistula formation
- Toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (except for low-risk toxicities)
- Active hepatitis B, hepatitis C, HIV infection, or active syphilis
- Known allergy to the investigational drug or its components, or history of severe hypersensitivity to other biologic agents
- Severe infection within 4 weeks prior to dosing, or active infection requiring systemic therapy within 2 weeks
- Receipt of non-specific immunomodulatory therapy or antitumor traditional Chinese medicine within 2 weeks prior to dosing
- Receipt of live vaccines within 30 days prior to dosing or planned during the study period
- Pregnant or breastfeeding women, or individuals of childbearing potential who are not using highly effective contraception as required
- Individuals considered vulnerable populations (e.g., patients with psychiatric disorders or critically ill patients), or any other condition deemed unsuitable for enrollment by the investigator.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Sacituzumab tirumotecan in Previously Treated Locally Advanced or Metastatic PDAC
|
Sacituzumab tirumotecan 5 mg/kg administered intravenously every 2 weeks
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate (ORR)
Zeitfenster: From the date of first dose to the date of first documented disease progression as assessed by RECIST v1.1, death from any cause, or study discontinuation, whichever occurs first; tumor assessments performed every 6 weeks for up to 100 weeks.
|
Percentage of patients with Complete Response (CR) or Partial Response (PR) per RECIST
|
From the date of first dose to the date of first documented disease progression as assessed by RECIST v1.1, death from any cause, or study discontinuation, whichever occurs first; tumor assessments performed every 6 weeks for up to 100 weeks.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: LIN YANG, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCC6141
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .